Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radi
"This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic patients with solid tumor malignancies receiving SBRT. CD8+ T cells are mainly found in lymph
| Condition(s) | Metastatic Malignant Solid Neoplasm, Lymphoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | "This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic patients with solid tumor malignancies receiving SBRT. CD8+ T cells are mainly found in lymph tissue and play a significant role in anti-tumor immunity. These cells can infiltrate tumor cells and kill them. Radiation therapy may recruit CD8 T cells and this recruitment may help with tumor control. Diagnostic procedures, such as zirconium Zr 89-Df-crefmirlimab positron emission tomography (PET), may be a less invasive way to check and monitor for CD8+ T cells before and after radiation therapy." |
| Who can participate | Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Participant is willing and able to comply with all protocol required procedures * Age: \>= 18 years * Eastern Cooperative Oncology Group (ECOG) =\< 2 * Metastatic patients of any solid tumor malignancy amenable for SBRT as determined by the radiation oncologist * Lymphoma patients may be allowed as determined by the principal investigator (PI) * No change in systemic treatment regimen for past 2 months prior to start of SBRT * Patients able to comply with daily PET after SBRT * Patient meets all clinical safety lab values per institution's standard of care, or Investigator's discretion, for patients receiving cancer treatment * Women of childbearing potential (WOCBP): negative ur |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | City of Hope Medical Center |
| Locations | Duarte, California, United States |
| Start date | 2022-06-20 |
| NCT ID | NCT05371132 |
| Official listing | https://clinicaltrials.gov/study/NCT05371132 |